Drug Profile

TalGlobin 01

Alternative Names: Tal-Globin01

Latest Information Update: 13 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellectis
Class Antianaemics; Gene therapies; Stem cell therapies
Mechanism of Action Blood protein replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Sickle cell anaemia

Most Recent Events

11 Oct 2022 Pharmacodynamics data from preclinical study in Sickle cell anaemia released by Cellectis
11 Dec 2021 Pharmacodynamics data from preclinical studies in Sickle cell anaemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
11 Dec 2021 Pharmacodynamics data from preclinical studies in Sickle cell anaemia released by Cellectis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com